Scholarlink

<p>Pathological fibrosis is a chronic process characterized by excessive deposition of extracellular matrix (ECM), which disrupts tissue architecture and function and accelerates disease progression in organs such as the lungs, liver, heart, kidneys, skin, and eyes. Recent studies have identified leucine-rich α-2 glycoprotein-1 (LRG1), a secreted glycoprotein known for modulating angiogenesis and immune responses, as a key player in the pathogenesis of fibrotic disorders. LRG1 expression is up-regulated by multiple pro-fibrotic mediators, including transforming growth factor-beta (TGF-β), and has been shown to regulate fibroblast differentiation, myofibroblast activation, and ECM production. Through interactions with the TGF-β signaling pathway and other cascades, LRG1 plays a crucial role in pathological fibrosis. Elucidating the molecular mechanisms by which LRG1 drives fibrogenic responses will pave the way for novel therapeutic strategies targeting pathological fibrosis. This review explores the emerging functions of LRG1 in fibrosis of different organs and discusses therapeutic approaches aimed at mitigating fibrosis through LRG1 inhibition.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The critical role of LRG1 in pathological fibrosis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月10日

查看全文
  • Tianxiang Yang,
  • Heping Xu

摘要

Pathological fibrosis is a chronic process characterized by excessive deposition of extracellular matrix (ECM), which disrupts tissue architecture and function and accelerates disease progression in organs such as the lungs, liver, heart, kidneys, skin, and eyes. Recent studies have identified leucine-rich α-2 glycoprotein-1 (LRG1), a secreted glycoprotein known for modulating angiogenesis and immune responses, as a key player in the pathogenesis of fibrotic disorders. LRG1 expression is up-regulated by multiple pro-fibrotic mediators, including transforming growth factor-beta (TGF-β), and has been shown to regulate fibroblast differentiation, myofibroblast activation, and ECM production. Through interactions with the TGF-β signaling pathway and other cascades, LRG1 plays a crucial role in pathological fibrosis. Elucidating the molecular mechanisms by which LRG1 drives fibrogenic responses will pave the way for novel therapeutic strategies targeting pathological fibrosis. This review explores the emerging functions of LRG1 in fibrosis of different organs and discusses therapeutic approaches aimed at mitigating fibrosis through LRG1 inhibition.